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Abstract
Although excessive fructose intake is epidemiologically linked with dyslipidemia, obesity, and diabetes, the mechanisms
regulating plasma fructose are not well known. Cells transfected with sodium/glucose cotransporter 5 (SGLT5), which is
expressed exclusively in the kidney, transport fructose in vitro; however, the physiological role of this transporter in fructose
metabolism remains unclear. To determine whether SGLT5 functions as a fructose transporter in vivo, we established a line
of mice lacking the gene encoding SGLT5. Sodium-dependent fructose uptake disappeared in renal brush border
membrane vesicles from SGLT5-deficient mice, and the increased urinary fructose in SGLT5-deficient mice indicated that
SGLT5 was the major fructose reabsorption transporter in the kidney. From this, we hypothesized that urinary fructose
excretion induced by SGLT5 deficiency would ameliorate fructose-induced hepatic steatosis. To test this hypothesis we
compared SGLT5-deficient mice with wild-type mice under conditions of long-term fructose consumption. Paradoxically,
however, fructose-induced hepatic steatosis was exacerbated in the SGLT5-deficient mice, and the massive urinary fructose
excretion was accompanied by reduced levels of plasma triglycerides and epididymal fat but fasting hyperinsulinemia
compared with fructose-fed wild-type mice. There was no difference in food consumption, water intake, or plasma fructose
between the two types of mice. No compensatory effect by other transporters reportedly involved in fructose uptake in the
liver and kidney were indicated at the mRNA level. These surprising findings indicated a previously unrecognized link
through SGLT5 between renal fructose reabsorption and hepatic lipid metabolism.
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Introduction
Epidemiological studies and nutritional experiments have
shown that excessive consumption of fructose is closely linked
with metabolic abnormalities including dyslipidemia, obesity,
diabetes, and cardiovascular disease [1,2], and the dramatic
increase in consumption of fructose, which is used to sweeten a
wide variety of foods and soft drinks, has been proposed as a
possible causal factor [3,4]. In animal experiments, it is also shown
that high fructose intake induces these abnormalities [5,6].
Fructose is mainly metabolized by the liver, where it is a highly
lipogenic substrate [7]. High fructose concentration enhances
hepatic de novo lipogenesis and plays a critical role in the
pathogenesis of nonalcoholic fatty liver disease (NAFLD) and
may promote the transition from NAFLD to a more severe
pathophysiological phenotype: nonalcoholic steatohepatitis
(NASH) [8]. Excess triglyceride accumulation causes insulin
resistance by directly interfering with hepatic insulin signaling
[9]; however, it is still unclear whether there is a causal
relationship between hepatic steatosis and insulin resistance [10].
These fructose-induced metabolic abnormalities, which underlie
type 2 diabetes and cardiovascular diseases, are the reason that
fructose metabolism has recently begun to gain the attention of
researchers.
Most monosaccharides, including fructose, glucose, galactose,
and mannose, as well as myo-inositol are transported across the cell
membrane by either of two types of glucose transporters:
facilitated glucose transporters (GLUTs) and sodium/glucose
cotransporters (SGLTs). Several reports suggest that fructose is
transported across the intestinal epithelium by GLUT2 and
GLUT5 [11,12,13,14,15,16]. Especially, GLUT5 knockout mouse
[17] showed a 75% decrease of fructose absorption in the jejunum
and 90% decrease in serum fructose concentration, indicating the
primary role of GLUT5 in intestinal fructose absorption. Fructose
exists in a free form in the plasma and is rapidly absorbed into the
liver by GLUT2 and to a lesser extent into other tissues through
GLUT2, GLUT8, GLUT9, and GLUT12 [12,18,19], where it
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into the liver significantly enhances the rate of de novo lipogenesis
and triglyceride synthesis by up-regulating lipogenic enzymes [6].
Plasma fructose concentration is potentially regulated in the
kidney also. This is considered likely because plasma glucose
concentration is strictly regulated by renal glucose reabsorption in
addition to the glucose utilization in tissues such as the liver,
skeletal muscle, and adipose. SGLT1 and SGLT2 contribute to
the regulation of renal glucose uptake, and the induction of
urinary glucose excretion with SGLT2 inhibition has been shown
to reduce plasma glucose in clinical trials with diabetic patients
[20,21]. Several glucose transporters, such as GLUT2, GLUT5,
NaGLT1, and SGLT4, have been reported to transport fructose
and exist in the kidney [15,22,23,24]; however, the contribution of
these transporters to renal fructose transport in the regulation of
plasma fructose levels is not known. Additionally, it has been
recently reported that human SGLT5 is exclusively expressed in
the kidney and that, in in vitro experiments using cells
overexpressing human SGLT5, it mediates the transport of
fructose and mannose [25]; however, the actual physiological role
of SGLT5 in vivo has remained unknown.
In the current study, we generated mice lacking Slc5a10, the
gene encoding SGLT5. We first confirmed the activity of SGLT5
as a fructose transporter by using renal brush border membrane
vesicles (BBMVs) of the mice, and we then identified the function
of SGLT5 as a renal transporter that reabsorbs fructose. Since
inhibition of renal glucose reabsorption by an SGLT2 inhibitor
appears to be an attractive anti-diabetic strategy [20], we
hypothesized that inhibition of renal fructose reabsorption would
increase urinary excretion of fructose and thereby prevent
fructose-induced metabolic abnormalities. We tested this hypoth-




All mice were housed under a 12-h/12-h light/dark cycle (lights
on 7:00 AM–7:00 PM) with controlled room temperature (20–
26uC) and humidity (35–75%), and were allowed ad libitum access
to standard mouse chow (CE-2;Clea Japan, Tokyo, Japan). All
animal care and experiments were performed in accordance with
the guidelines for the care and use of laboratory animals at Chugai
Pharmaceutical Co., Ltd. The protocol was approved by the
Institutional Animal Care and Use Committee at Chugai
Pharmaceutical Co. Ltd. (Permit No. 11-237). All surgery was
performed under isoflurane anesthesia, and all efforts were made
to minimize suffering.
Generation of SGLT5-deficient mice and genotyping
The Slc5a10 knockout mouse was established basically by the
same protocol as we described previously [26,27,28] with some
modifications. The protocol is briefly described as follows. A clone
of a bacterial artificial chromosome (BAC) carrying C57BL/6 (B6)
mouse genomic DNA containing all exons of the Slc5a10 gene was
engineered by using the Red/ET system (Gene Bridges, Heidel-
berg, Germany) for construction of a Slc5a10 gene-targeting vector
[29,30]. The targeting vector was introduced by electroporation
into B6 mouse embryonic stem cells (ES cells). Homologous
recombinant ES cell clones were injected into BALB/c mouse
blastocysts to produce chimeric mice. Chimeric mice were bred
with B6 females to establish Slc5a10 gene-deficient mice, which
were named B6-Slc5a10
tm1Csk. Heterozygous mice were inter-
crossed to produce homozygous mice. Polymerase chain reaction
(PCR) for genotyping was performed with a common forward
primer Sg5-4401 (59-AGTACACAGGGACTGTCAGGC-39)
and different reverse primers: SgR-5309 (59- GGAGCTTCT-
TACGGATGTCT-39) for wild-type and Neo-anti4 (59-
AACTTCCTGACTAGGGGAGGAGTA-39) for null allele.
Tissue distribution analysis of mouse SGLT5
Expressions of mouse SGLT5 (mSGLT5) were determined by
using mouse 1st strand cDNA (GenoStaff, Tokyo, Japan).
Quantitative RT-PCR was performed on an ABI 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA) using
primers specific for SGLT5. Expression of GAPDH was used as an
internal control.
Uptake experiments in COS-7 cells
Expression plasmids containing human SGLT5 (hSGLT5) and
mSGLT5 were prepared by the ligation of fragments, amplified
from Human Kidney Marathon-Ready cDNA (Clontech Labora-
tories, Mountain View, CA) or cDNA fragments prepared from
the kidney of db/db mouse with primers designed from published
sequences (GenBank accession numbers: NM001042450,
NM001033227), into the multi-cloning site of pcDNA3.1(2) (Life
Technologies Corporation [Invitrogen], Grand Island, NY). The
expression plasmids containing hSGLT5 or mSGLT5 cDNA
fragments were transfected into African green monkey SV40-
transfected kidney fibroblast cells (COS-7; ATCC), and the cells
transiently expressing each SGLT were used for the fructose
uptake assay. For fructose uptake assay, the cells expressing each
SGLT were cultured in 96-well plates for 2 days and washed twice
with sodium-free buffer (140 mM choline chloride, 2 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES-Tris, pH 7.4). The
cells were then incubated in the sodium-free buffer or in sodium
buffer (140 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
10 mM HEPES-Tris, pH 7.4) each containing 0.1 mM fructose
(mixture of non-radiolabeled fructose and [
14C]-fructose (Moravek
Biochemicals, Brea, CA)) at 37uC for 40 min. Sodium-dependent
fructose uptake was calculated by subtracting the radioactivity
detected in cells incubated in the sodium-free buffer from the
radioactivity detected in the cells incubated in the sodium buffer.
Preparation of renal brush border membranes (BBMs)
Kidneys were collected from anesthetized mice and homoge-
nized in ice-cold isolation buffer (50 mM mannitol, 2 mM Hepes-
Tris, pH 7.1) with an Ace homogenizer (Model AM-1; Nissei,
Tokyo, Japan) at 18,000 rpm for 2 min. CaCl2 (1 M) was added to
give a final concentration of 10 mM. After stirring for 20 min at
4uC, the suspension was centrifuged at 3,0006g for 15 min at 4uC.
The supernatant was then centrifuged at 39,8006g for 30 min at
4uC. The pellets were suspended in suspension buffer (100 mM
mannitol, 10 mM Hepes-Tris, pH 7.5) and homogenized with a
Teflon homogenizer on ice. The samples were centrifuged at
39,8006g for 30 min at 4uC. The final pellets containing the
BBMs were suspended in suspension buffer and stored at 280uC
until use. Determination of activity of membrane marker enzymes
revealed enrichment of alkaline phosphatase (ALP) in the final
membrane preparations.
Renal brush border membrane vesicle (BBMV) assay
The protein concentration of the BBM suspensions was adjusted
to 6.3 mg/mL with suspension buffer. The samples were then
suspended by passing 10 times through a 22- and 27-gauge needle.
Uptake reaction was initiated by adding 20 mL of membrane
suspension to 20 mL potassium buffer (100 mM KCl, 50 mM
Fructose Transporter SGLT5 and Hepatic Steatosis
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cals, Brea, CA). Mixed samples were incubated for 10 s at 25uC.
Incubation was terminated by adding 1 mL ice-cold stop solution
containing 100 mM fructose or mannnose, followed by filtration.
The mixture was poured immediately onto nitrocellulose mem-
brane filters (Millipore, Billerica, MA), and the filters were washed
with 5 mL of ice-cold stop buffer. The radioactivity of the filter
was counted in 10 mL Clear-sol I (Nacalai Tesque, Tokyo, Japan)
by a Tricarb 3110TR scintillation counter (PerkinElmer, Boston,
MA). Sodium-independent fructose or mannose uptake was
calculated from the radioactivity detected in the sample incubated
in the sodium-free buffer. Sodium-dependent fructose or mannose
uptake was calculated by subtracting the radioactivity detected in
the sample incubated in the sodium-free buffer from the
radioactivity detected in the sample incubated in the sodium
buffer.
Long-term fructose consumption
Wild type (WT) C57BL/6 mice and SGLT5-deficient mice
(n=8–10 per group, 11-week-old male) had free access to 30%
(wt/vol) fructose water or plain water for 11 weeks. Plasma glucose
levels, body weight, food intake, and water intake were measured
periodically. Plasma glucose levels were measured by a plasma
glucose monitoring system (Accu-Chek Aviva; Roche Diagnostics,
Tokyo, Japan). The mice were maintained in metabolic cages and
24-h urine samples were collected at 21 weeks of age. Then an oral
glucose challenge (2 g/kg) was administered to the conscious mice
after fasting for 16 h, and the plasma glucose levels were measured
at 30, 60, 120, 180 min after glucose ingestion. At 22 weeks of age,
plasma, liver, kidney, and epididymal fat were collected from each
mouse under anesthesia with isoflurane.
Hepatic triglyceride determination
Livers were homogenized in PBS/methanol (1:2.5). The same
volume of chloroform as PBS was added to the homogenate and
mixed vigorously. The samples were centrifuged at 1,2006g for
10 min. The lower layer was collected, dried, and suspended in
isopropyl alcohol. Hepatic triglyceride level was quantified with a
Triglyceride E-test kit (Wako Pure Chemicals, Osaka, Japan).
Histopathology
Collected livers were embedded in OCT compound (Sakura
Finetek, Tokyo, Japan) in cryomolds and frozen in liquid nitrogen.
Liver sections were cut and stained with Sudan III, hematoxylin-
eosin (HE) and Sirius red by Sapporo General Pathology
Laboratory Co., Ltd, Sapporo, Japan) and then examined under
a light microscope.
Biochemical analysis
Biochemical analysis for plasma total cholesterol, triglycerides,
alanine aminotransferase (AST), aspartate aminotransferase
(ALT), lactate dehydrogenase (LDH), alkaline phosphatase
(ALP), creatine kinase, total bilirubin, urea nitrogen, creatinine,
and albumin was done with an automated chemistry analyzer
(TBA-120FR; Toshiba Medical Systems, Tokyo, Japan). Urinary
and plasma fructose concentrations were measured with a
commercially available kit (Enzytec fluid D-Glucose/D-Fructose;
J.K. International, Tokyo, Japan). Plasma insulin levels were
determined with an insulin ELISA kit (Morinaga Institute of
Biological Science, Kanagawa, Japan).
Expression analysis of transporters in the liver and kidney
Total RNA was isolated from the liver and kidney using an
RNeasy Minikit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Quantitative RT-PCR was performed
on an ABI PRISM 7900 Sequence Detection System (Applied
Biosystems) using the QuantiTect Probe RT-PCR Kit with probes
specific for transcripts of each transporter or MAPK1. Relative
gene expression was calculated with the 2
2DCt method using
MAPK1 as an endogenous control.
Microarray experiments
From the livers of WT mice and SGLT5-deficient mice that had
been given either plain water or fructose water we isolated total
RNA by using an RNeasy Minikit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. RNA quality was
determined by analysis on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). For profiling gene expression in
the liver, Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara,
CA) were hybridized with RNA isolated from livers in each of the
four groups, washed, and scanned according to the standard
Affymetrix protocol. Expression profiles were analyzed using
Genespring GX 11.5.1 software (Agilent Technologies). After
background correction, we performed normalization using
GCRMA. Genes were filtered by intensity values (lower cut off
percentile of 20% for raw signals) under each of the four
combinations of: +/+ Plain water; 2/2Plain water; +/+Fructose
water; 2/2 Fructose water. Gene activity was considered to differ
between conditions if P values were ,0.05 when compared by
one-way ANOVAs (with the false discovery rate (FDR) multiple
testing error correction procedure of Benjamini and Hochberg)
followed by Tukey’s post hoc test (with the same P cut-off value).
The array data has been submitted to the public microarray
database, ArrayExpress repository (Accession No. E-MEXP-3734;
http://www.ebi.ac.uk/arrayexpress)
Statistical analysis
Statistical analysis was performed with the SAS System for
Windows, Release 8.02 (SAS Institute Japan, Tokyo, Japan).
Statistical significance was determined by Student’s t-test unless
otherwise specified. P,0.05 was regarded as statistically signifi-
cant.
Results
SGLT5 expression in mouse kidney and fructose
transport
Firstly we confirmed mSGLT5 tissue expression in mice by
quantitative RT-PCR on a panel of mouse tissue samples. As
shown in Figure 1A, mSGLT5 was almost exclusively expressed in
the kidney; only slight expression of mSGLT5 was observed in the
testis, and no amplification product was obtained in the remaining
13 tissues. This expression pattern was similar to that of hSGLT5
[25]. To investigate the ability of SGLT5 to facilitate uptake of
fructose, we transiently transfected hSGLT5 or mSGLT5 into
COS-7 cells and performed uptake assays with
14C-labeled
fructose. We observed that both human and mouse SGLT5
transported fructose in a sodium-dependent manner (Figure 1B).
Generation of SGLT5-deficient mice
We generated SGLT5-deficient mice by disruption of the
Slc5a10 gene in ES cells by using standard homologous recombi-
nation techniques (Figure 2A). A representative result of PCR
analysis for genotyping is shown in Figure 2B. Homozygous null
Fructose Transporter SGLT5 and Hepatic Steatosis
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inheritance and have no apparent morphological abnormalities.
Fructose and mannose uptake by renal BBMV from
SGLT5-deficient mice
To confirm that SGLT5 transports fructose in renal tubules, we
assayed renal BBMVs prepared from the kidneys of WT or
SGLT5-deficient mice. Figure 2C shows sodium-dependent
uptake of fructose in BBMVs. In the presence of 0.1 mM and
1 mM fructose, the fructose uptake observed in BBMVs from WT
mice was absent in BBMVs from SGLT5-deficient mice. The
sodium-independent uptake of fructose was observed with lesser
activity compared to sodium-dependent uptake, and no significant
differences in the sodium-independent fructose uptake between
WT and SGLT5-decficient mice (Figure 2E). Mannose uptake was
also observed in BBMVs from WT mice, but the activity was lower
than that observed for fructose uptake (Figure 2D). The sodium-
dependent mannose uptake was also observed in BBMVs from
WT mice, but the activity was lower than that observed for
fructose uptake and this mannose transport activity in BBMVs
from mice lacking SGLT5 was lower than that in normal BBMVs
(Figure 2D). The sodium-independent uptake of mannose was not
significantly different between WT and SGLT5-decficient mice
(Figure 2F). The sodium-dependent glucose and galactose uptake
were not affected by SGLT5 deficiency (data not shown). These
results clearly show that mSGLT5 functions mainly as a fructose
and also as a mannose transporter in the kidney.
Urinary fructose reabsorption in SGLT5-deficient mice
Since sodium-dependent fructose transport was impaired in
BBMVs of SGLT5-deficient mice, we investigated whether
SGLT5 affected fructose metabolism in vivo. WT and SGLT5-
deficient mice (n=8–10, 11 weeks old) had free access to 30%
fructose water or plain water for 11 weeks. Although fructose
consumption reduced food intake and raised water intake, and
slightly increased total energy intake per day, no differences in
Figure 1. SGLT5 distribution and fructose uptake. (A) Tissue distribution of mouse SGLT5 and (B) SGLT5-mediated fructose uptake in COS-7
cells. Data are presented as means 6 S.D. Data are derived from 3 independent experiments.
doi:10.1371/journal.pone.0056681.g001
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SGLT5-deficient mice (Figure 3A, B, C). WT and SGLT5-
deficient mice given 30% fructose water respectively received
58.7% and 56.7% of their daily energy intake as fructose. During
the experimental period, fructose intake increased plasma glucose
levels and body weights, but there was no significant difference
between WT and SGLT5-deficient mice (Figure 4A, B). Blood
insulin level tended to increase in WT mice and SGLT5-deficient
mice given fructose, and in SGLT5-deficient mice this increase in
insulin was significant (Figure 4C).
Urine and plasma samples were collected at 21 and 22 weeks of
age, respectively. As shown in Figure 4D, there was no significant
difference in plasma fructose levels between groups. In mice given
plain water, urinary fructose excretion was extremely low but was
obviously higher in SGLT5-deficient mice than in WT mice
(Figure 4E). When given high fructose water, urinary fructose
excretion was elevated in both WT and SGLT5-deficient mice.
The amount of urinary fructose of SGLT5-deficient mice was
considerably higher than that of normal mice (Figure 4F). These
results clearly show that there is a defect in the renal fructose
reabsorption system in SGLT5-deficient mice, which leads to
massive urinary fructose excretion.
Long-term effect of fructose consumption in SGLT5-
deficient mice
Excess fructose intake leads to increased hepatic triglyceride
levels in animals [31,32]. Since an excessive amount of fructose
was excreted by SGLT5-deficient mice as compared to WT mice,
we examined the hypothesis that inhibition of renal fructose
reabsorption would accelerate fructose disposition and thereby
prevent fructose-induced metabolic abnormalities in these mice.
In WT mice, high fructose intake decreased plasma triglyceride
level (Figure 5A) but increased plasma total cholesterol level
(Figure 5B), epididymal fat amount (Figure 5C), liver weight
(Figure 5D), and hepatic triglyceride level (Figure 5E). In SGLT5-
deficient mice, levels of plasma triglycerides and epididymal fat
were found to be lower than those in WT mice, both with plain
water consumption and with fructose water consumption
(Figure 5A, C). But plasma total cholesterol concentration in
SGLT5-deficient mice was not different from that in WT mice
under either of these conditions (Figure 5B). To our surprise,
however, triglycerides were massively accumulated in the liver of
SGLT5-deficient mice receiving 30% fructose water (Figure 5E).
The elevated hepatic triglyceride content was associated with
increased liver weight and severe hepatic steatosis (Figure 5D, F) as
shown by the increased ratio of mice with severe accumulation of
Figure 2. Generation of SGLT5-deficient mice and their fructose and mannose uptake by renal BBMV s. (A) Schematic representation of
the strategy for targeting the Slc5a10 gene. A targeting vector was constructed by inserting a neomycin resistant (neo) gene cassette to disrupt exons
3–6 of the Slc5a10 genomic locus on a BAC genomic clone. Arrows indicate PCR primers for genotyping. (B) A representative result of genotyping the
offspring obtained by intercrossing heterozygous-deficient mice. Wild type and null alleles are detected as signals of 900 bp and 350 bp, respectively.
Wt: Wild type mice, He: Heterozygous null mutant, Ho: Homozygous null mutant. (C) Sodium-dependent uptake of fructose and (D) mannose in
BBMVs of WT mice (+/+) and SGLT5-deficient mice (2/2). (E) Sodium-independent uptake of fructose and (F) mannose in BBMVs of WT mice (+/+)
and SGLT5-deficient mice (2/2). Data are presented as means 6 S.D. Data are derived from 3 independent experiments.
doi:10.1371/journal.pone.0056681.g002
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inflammatory or fibrogenic changes were detected in the HE or
Sirius red-stained liver sections of the SGLT5-deficient mice
receiving 30% fructose water, except for increased vacuolation
(data not shown), which may be due to the increased accumulation
of lipid droplets.
An oral glucose tolerance test revealed that both the WT and
the SGLT5-deficient mice given water containing fructose
exhibited glucose intolerance, but no significant difference
between WT and SGLT5-deficient mice was observed (Figure 6).
The severe fatty liver observed in SGLT5-deficient mice was also
associated with increased plasma ALT and AST, which are
commonly used parameters reflecting hepatic impairment,
including NAFLD (Table 1) [33]. Additionally, LDH, a tissue
injury marker, was increased in SGLT5-deficient mice given
fructose water (Table 1) [34].
Gene expression analysis
Excessive accumulation of hepatic triglycerides in SGLT5-
deficient mice led us firstly to examine the possibilities that the lack
of fructose uptake via SGLT5 induces up-regulation of other
fructose transporters in the liver or compensation in the kidney.
We therefore performed quantitative RT-PCR to determine
expression levels of transporters possibly involved in fructose
uptake in the liver and kidney; these included SGLT4, SGLT5,
GLUT2, GLUT5, GLUT8, GLUT9, GLUT12, NaGLT1a,
NaGLT1b, and NaGLT1c. In the liver, there was no significant
difference between groups in the expression levels of the
transporters, suggesting that hepatic fructose absorption might
be normal in SGLT5-deficient mice (Figure 7A). In the kidney,
SGLT5 was up-regulated in WT mice receiving fructose.
However, there was no change in the expression levels of the
nine transporters other than SGLT5 between fructose-fed WT
mice and SGLT5-deficient mice (Figure 7B). These results
precluded the possibility that any of these nine other transporters
examined here contributed to the exaggeration of hepatic
triglyceride accumulation in SGLT5-deficient mice.
Next, to obtain insight into the molecular mechanisms
underlying the exacerbation of hepatic steatosis induced by
fructose in the SGLT5-deficient mice, we used microarray analysis
to compare the liver gene expression patterns of the four groups
(Figure S2). We first examined the effect of fructose consumption
Figure 3. Food and water intake in WT (+/+) mice and SGLT5-deficient mice (2/2). Daily intake of (A) food and (B) water of mice at
17 weeks of age. (C) Calculated daily energy intake. Data are presented as means 6 S.E.M (n=8–10). ### P,0.001 versus respective plain water
control.
doi:10.1371/journal.pone.0056681.g003
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PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e56681Figure 4. Effect of high fructose consumption in WT mice and SGLT5-deficient mice. (A) Plasma glucose levels of WT mice (+/+) and SGLT5-
deficient mice (2/2) were measured every 2 weeks. HF: Mice given water containing high fructose. (B) Growth curves of WT mice and SGLT5-
deficient mice. (C) Plasma samples were collected after 6 h fasting at 21 weeks of age, and immunoreactive insulin (IRI) was determined. (D) Plasma
fructose concentrations measured in plasma samples collected under anesthesia after 3 h fasting. Open circles represent individual data. (E and F) WT
mice and SGLT5-deficient mice given plain water or fructose water were maintained in metabolic cages and 24-h urine samples were collected.
Urinary fructose excretion was calculated by multiplying urinary fructose concentration by the amount of urine. Data are presented as means 6 S.E.M
(n=8–10). *** P,0.001 versus WT mice given 30% fructose water. # P,0.05, ## P,0.01, ### P,0.001 versus respective plain water controls. +++
P,0.001 versus WT mice given plain water.
doi:10.1371/journal.pone.0056681.g004
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sets on the microarray, fructose consumption increased expression
of 86 probe sets (fold change of 1.5 or more) with respect to
average expression in WT mice given plain water. Of these, probe
sets for the leptin receptor and ApoA4 genes were those most
induced (fold change of approx. 10). On the other hand, we
observed 103 down-regulated probe sets (fold change of 1.5 or
more) with fructose consumption (data not shown). We then
Figure 5. Influence of the long-term consumption of fructose on tissue weight and lipid metabolism. (A) Plasma triglyceride levels of WT
mice (+/+) and SGLT5-deficient mice (2/2). (B) Plasma total cholesterol levels. (C) Weight of epididymal fat. (D) Weight of the liver. (E) Hepatic
triglyceride levels. (F) Histopathological analysis of the liver sections. Two sections per mouse were stained with Sudan III. Representative images are
shown (scale bar, 50 mm). Data are presented as means 6 S.E.M (n=8–10). * P,0.05, *** P,0.001 versus WT mice given 30% fructose water. #
P,0.05, ## P,0.01, ### P,0.001 versus respective plain water controls.
doi:10.1371/journal.pone.0056681.g005
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mice, but only minimal changes, and no changes in lipogenic
factors including target genes of SREBP-1 and gluconeogenic and
glycolytic enzymes were observed (Table S2). Interestingly, the
probe set for Cyp17a1 was increased by fructose consumption in
WT mice (fold change of 3.17) and further increased in SGLT5-
deficient mice (fold change of 4.46); however, to our knowledge,
there is no report indicating a relationship between triglyceride
metabolism and the enzyme encoded by this gene.
Discussion
In the present study, we identified the function of SGLT5 as a
renal fructose reabsorption transporter by showing that sodium-
dependent fructose uptake was diminished in renal BBMVs from
Figure 6. Oral glucose tolerance test with WT mice (+/+) and
SGLT5-deficient mice (2/2) given plain water or fructose water
(HF). Fasted 21-week-old male mice received an oral dose of glucose
(2 g/kg). Plasma glucose levels were determined at the indicated time
points. Data are presented as means 6 S.E.M (n=8–10). ### P,0.001
versus respective water controls by analysis of covariance (ANCOVA).
doi:10.1371/journal.pone.0056681.g006
Table 1. Characteristics of 22-week-old WT mice (+/+) and SGLT5-deficient mice (2/2) receiving plain water or fructose water
(HF).
+/+ 2/2 +/+ (HF) 2/2 (HF)
AST (U/L) 33.760.8 43.468.1 39.961.3### 5867.1*
ALT (U/L) 24.461.9 27.164.2 29.761.8 63.3613.4*#
ALP (U/L) 186.364.9 196.9614.2 259.967.0### 291.6623.0##
LDH (U/L) 172.168.1 184.1619.0 211.3610.6## 293630.9*#
Creatine kinase (U/L) 58.665.3 69.365.3 111.4654.9 109.6621.8
Total bilirubin (mg/dl) 0.07960.004 0.160.029 0.08260.005 0.08960.006
BUN (mg/dl) 21.761.0 19.8160.062 14.060.7### 15.360.7###
Creatinine (mg/dl) 0.06160.002 0.06460.003 0.06760.003 0.07360.012
Albumin (g/dl) 2.7560.048 2.7660.043 3.0760.021### 3.260.069*###
Data are presented as means 6 S.E.M (n=8–10).
*P,0.05 versus WT mice given 30% fructose water.
#P,0.05,
##P,0.01,
###P,0.001 versus respective plain water controls. AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, LDH: lactate
dehydrogenase, BUN: blood urea nitrogen.
doi:10.1371/journal.pone.0056681.t001
Figure 7. Gene expression analysis. Quantitative RT-PCR was
performed with total RNA isolated from (A) the liver and (B) the
kidney of WT mice (+/+) and SGLT5-deficient mice (2/2) given
plain water or high fructose (HF) water. MAPK1 was used as an
internal control. Data are presented as means 6 S.E.M. n=3 (A). n=8–
10 (B).
doi:10.1371/journal.pone.0056681.g007
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SGLT5-deficient mice. SGLT5 deficiency increased urinary
fructose excretion without affecting plasma fructose concentrations
and reduced plasma triglyceride levels. Unexpectedly, however,
SGLT5 deficiency paradoxically exacerbated hepatic steatosis
induced by long-term fructose consumption. The current results
showed that inhibition of renal fructose reabsorption did not
prevent fructose-induced metabolic abnormalities by increasing
urinary fructose excretion. Instead, an intriguing link through
SGLT5 between fructose reabsorption and hepatic lipid metab-
olism is suggested.
It is known that GLUT5, a fructose transporter, is present on
the apical membrane of renal proximal tubules [35] in addition to
being in the intestine, where it plays a critical role in fructose
absorption [13,14,15,17]. NaGLT1 is also known to be involved in
fructose absorption in rat kidneys [23]. Both GLUT5 and
NaGLT1, however, are low-affinity fructose transporters with
respective Km values for fructose of 6 mM and 7.8 mM [12,23].
Under normal conditions, physiological blood fructose concentra-
tions are much lower than those values (under 0.05 mM) both in
humans [36,37] and in our WT mice, suggesting the existence of a
high-affinity fructose transporter. Although Horiba et al. reported
high-affinity fructose transport activity (Km value of 0.3 mM) in rat
kidneys [23], the molecular entity of that transporter remains
unknown. In this study, we observed sodium-dependent uptake of
fructose at 0.1 mM via SGLT5 in COS-7 cells and in wild-type
mice BBMVs, which lose their fructose uptake ability in SGLT5-
deficient mice. These findings, together with the other data in this
study, suggest that SGLT5 is a high-affinity fructose transporter
that potentially functions in the kidneys of humans and rodents.
GLUT5 is expressed only in the S3 segment of renal proximal
tubules [35]. Because the basolateral fructose transporter GLUT2
is localized only in S1 and S2 [38], transporters other than
GLUT5 can also be working on the apical side of these segments.
In situ hybridization shows that SGLT2, which exists in segments
S1 and S2 [39], and SGLT5 are co-expressed in epithelial tissue of
the glomerulus and distal and proximal tubules [40]. Although we
have no direct evidence showing the presence of this transporter in
proximal tubules because a specific SGLT5 antibody is not
available, we looked at fructose uptake in a BBMV assay. This
assay method had been validated by testing the effect of several
SGLT2 inhibitors on sodium-dependent glucose transport (data
not shown) and, in the case of sodium-dependent fructose
transport, detected it only in wild-type mice. Taking this result
together with the results of the present in vivo study, in which
SGLT5 deficiency increased urinary fructose excretion, we suggest
that SGLT5, a high-affinity fructose transporter, incorporates
fructose at the apical membrane of the proximal tubule in
collaboration with GLUT2 and contributes primarily to renal
fructose reabsorption.
Since accelerated urinary excretion of fructose was demonstrat-
ed in SGLT5-deficient mice, we used these mice under conditions
of high fructose consumption to test the hypothesis that inhibition
of renal fructose reabsorption would prevent fructose-induced
metabolic abnormalities. SGLT5 deficiency obviously elevated
fructose excretion. Nonetheless, compared with fructose-fed WT
mice, fructose-fed SGLT5-deficient mice exhibited more severe
hepatic steatosis, which was associated with raised levels of
inflammatory and tissue damage markers including AST and
ALT. Since the fructose intake of WT mice and SGLT5-deficient
mice was equivalent, and SGLT5 deficiency facilitated fructose
excretion, the abnormal lipid accumulation observed in the liver of
SGLT5-deficient mice is not accounted for by a quantitative
balance between intake and excretion of fructose. These findings
indicate that fructose-induced metabolic abnormalities are not
ameliorated by inhibiting renal fructose reabsorption through
SGLT5 deficiency, and that there may be unique features involved
in SGLT5 deficiency.
To investigate the cause of exacerbated hepatic steatosis in
SGLT5-deficient mice, we compared the gene expression levels of
possible fructose transporters in the kidney and in the liver.
However, there was no significant difference in expression levels
between WT and SGLT5-deficient mice, suggesting that the cause
of exacerbated hepatic steatosis is not likely to be excess fructose
uptake in these tissues. Nevertheless, we cannot exclude the
possibility of increases in the protein levels of other fructose
transporters or increases in the translocation of GLUTs to the cell
surface. De novo extra-hepatic lipogenesis, such as adipogenesis, is
probably not the major causative factor of the increased level of
hepatic triglycerides in SGLT5-deficient mice because consump-
tion of fructose-containing water resulted in decreased levels of
plasma triglycerides and epididymal fat compared to levels in
fructose-fed WT mice. Although decreased hepatic lipoprotein
secretion is a possible explanation, this is not supported by the
similar plasma total cholesterol levels in the SGLT5-deficient and
WT mice consuming fructose.
From these results and the discussion above, we speculated that
hepatic de novo lipogenesis is further enhanced by SGLT5 deletion.
Although our liver gene expression profiling using a microarray
did not support this speculation, other mechanisms such as post-
transcriptional regulation (e.g., processing of SREBP-1c precursor
to the active nuclear form) might be a possible mechanism. This
and previous studies [25] indicate that SGLT5 also transports
mannose, suggesting that impaired processes of glycosylation
involving mannose is another possibility.
Increased insulin resistance is implicated by the finding that
fasting insulin and glucose intolerance increased in SGLT5-
deficient mice under fructose consumption. Hepatic insulin
resistance is also suggested by the lack of change in the liver gene
expression profile of lipogenic factors, including target genes of
SREBP-1, gluconeogenic enzymes, and glycolytic enzymes;
however, this finding also suggests lipid accumulation per se is
not regulated at transcriptional level. The complexity of insulin
action, which uses a variety of mechanisms, including post-
transcriptional regulation, and is itself modulated both by allosteric
regulation of responsible enzymes and by the availability of
substrates for lipogenesis and gluconeogenesis, means that further
study will be needed to understand the causal relationship between
hepatic steatosis insulin resistance and fructose metabolism in the
liver and kidney.
Although details of the mechanisms underlying the increased
levels of hepatic triglycerides in SGLT5-deficient mice remain
unclear for now, our finding has important implications with
respect to a previously unknown link between the renal fructose
reabsorption system and hepatic lipid metabolism. Further
investigations elucidating the molecular mechanisms underlying
this link would provide a new therapeutic option with which to
combat metabolic disorders such as hepatic steatosis, dyslipidemia,
obesity, and diabetes.
Supporting Information
Figure S1 Representative figures of the liver sections
from WT mice and SGLT5-deficient mice receiving plain
water or fructose water. ±, +, ++, +++: see grade of lipid
droplets in Table S1. Staining: Sudan III (scale bar: 50 mm).
(PDF)
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12 samples (4 conditions) and 469 genes. Of the 45,101
genes represented in the microarray, 469 genes were altered
between conditions (P,0.05 with a false discovery rate). The fold
change ratio was calculated with respect to the average intensity of
Condition 1. Purple is up-regulated and blue is down-regulated
with respect to the average intensity of Condition 1; black indicates
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